Stryker OP-1
This article was originally published in The Gray Sheet
Executive Summary
Orthopedic recombinant human protein European launch is slated for the third quarter following CE mark approval May 17. The device is indicated for treatment of non-union fractures of the tibia of at least nine months duration in skeletally mature patients in cases where previous autograft has failed or use of autograft is not feasible. In the U.S., the firm continues its discussions with FDA after the agency issued a not-approvable letter for the product in January due to insufficient radiographic data (1"The Gray Sheet" Feb. 5, 2001, p. 7)
You may also be interested in...
Stryker OP-1 Gains HDE Status For Failed Long-Bone Nonunion Fractures
Stryker plans to begin making its OP-1 (Osteogenic Protein 1) bone morphogenetic protein implant available in the U.S. by year-end under a humanitarian device exemption received from FDA Oct. 17, becoming the first company to have a BMP product reach the U.S. market.
Stryker OP-1 Gains HDE Status For Failed Long-Bone Nonunion Fractures
Stryker plans to begin making its OP-1 (Osteogenic Protein 1) bone morphogenetic protein implant available in the U.S. by year-end under a humanitarian device exemption received from FDA Oct. 17, becoming the first company to have a BMP product reach the U.S. market.
Stryker Will Discuss Rejected OP-1 PMA At Upcoming Meeting With FDA
Stryker expects to meet with FDA by March 1 to discuss the agency's "not approvable" letter for OP-1 bone growth factor for treating nonunion fractures.